Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective

Frontiers in Oncology

Sophia C. Kamran¹  Keyan Salari²  Dimitar V. Zlatev²  Xin Gao³  Thomas S. C. Ng⁴  Pedram Heidari⁴ 

[1] Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States;Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States;Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States;Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States;

关键词: PSMA;    PET;    prostate cancer;    radiation;    theranostics;    therapy;   

DOI  :  10.3389/fonc.2021.722277

来源: DOAJ

【 摘 要 】

Recent developments in prostate-specific membrane antigen (PSMA) targeted diagnostic imaging and therapeutics (theranostics) promise to advance the management of primary, biochemically recurrent, and metastatic prostate cancer. In order to maximize the clinical impact of PSMA-targeted theranostics, a coordinated approach between the clinical stakeholders involved in prostate cancer management is required. Here, we present a vision for multidisciplinary use of PSMA theranostics from the viewpoints of nuclear radiology, medical oncology, urology, and radiation oncology. We review the currently available and forthcoming PSMA-based imaging and therapeutics and examine current and potential impacts on prostate cancer management from early localized disease to advanced treatment-refractory disease. Finally, we highlight the clinical and research opportunities related to PSMA-targeted theranostics and describe the importance of multidisciplinary collaboration in this space.

【 授权许可】

Unknown